Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Exact Sciences Corporation (EXAS : NSDQ)

• Company Description    Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients. Number of Employees: 7,000

• Price / Volume Information    Yesterday's Closing Price: $103.36 Daily Weekly Monthly 20 Day Moving Average: 2,257,848 shares Shares Outstanding: 190.89 (millions) Market Capitalization: $19,730.21 (millions) Beta: 1.42 52 Week High: $103.54 52 Week Low: $38.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.86% 0.78% 12 Week 1.88% 0.87% Year To Date 1.77% 1.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5505 ENDEAVOR LANE - MADISON,WI 53719 USA ph: 608-535-8815 fax: 608-284-5701 investorrelations@exactsciences.com http://www.exactsciences.com

• General Corporate Information    Officers Kevin T. Conroy - President; Chief Executive Officer and Chairman Aaron Bloomer - Executive Vice President and Chief Financial Offic Mike Barber - Director Paul Clancy - Director D. Scott Coward - Director Peer Information Exact Sciences Corporation (CORR.) Exact Sciences Corporation (RSPI) Exact Sciences Corporation (CGXP) Exact Sciences Corporation (BGEN) Exact Sciences Corporation (GTBP) Exact Sciences Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30063P105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/07/26 Share - Related Items Shares Outstanding: 190.89 Most Recent Split Date: (:1) Beta: 1.42 Market Capitalization: $19,730.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.45 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 30.30% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/07/26

• Fundamental Ratios P/E Current FY Estimate: 71.28 Trailing 12 Months: 2,584.00 PEG Ratio: 2.35 Price Ratios Price/Book: 8.21 Price/Cash Flow: 81.61 Price / Sales: 6.08 EPS Growth vs. Year Ago Period: -250.00% vs. Previous Quarter: -187.50% Sales Growth vs. Year Ago Period: 23.12% vs. Previous Quarter: 3.25% ROE 12/31/25 - 0.53 09/30/25 - 1.67 06/30/25 - -1.75 ROA 12/31/25 - 0.22 09/30/25 - 0.70 06/30/25 - -0.76 Current Ratio 12/31/25 - 2.43 09/30/25 - 2.72 06/30/25 - 2.89 Quick Ratio 12/31/25 - - 09/30/25 - 2.44 06/30/25 - 2.56 Operating Margin 12/31/25 - 0.40 09/30/25 - 1.32 06/30/25 - -1.56 Net Margin 12/31/25 - -6.40 09/30/25 - -32.01 06/30/25 - -34.19 Pre-Tax Margin 12/31/25 - -6.28 09/30/25 - -32.28 06/30/25 - -34.51 Book Value 12/31/25 - 12.58 09/30/25 - 13.21 06/30/25 - 13.09 Inventory Turnover 12/31/25 - 5.80 09/30/25 - 5.58 06/30/25 - 5.52 Debt-to-Equity 12/31/25 - 0.97 09/30/25 - 0.93 06/30/25 - 0.94 Debt-to-Capital 12/31/25 - 49.22 09/30/25 - 48.18 06/30/25 - 48.48

Powered by Zacks Investment Research ©